05-Jun-2020 - Université de Montréal

Tracking cancer's immortality factor

How a key cancer mutation activates telomerase, the ‘anti-aging enzyme’ that makes tumour cells immortal

Canadian scientists have achieved a first in the study of telomerase, an essential enzyme implicated in aging and cancer.

In the journal Molecular Cell, scientists from Université de Montréal used advanced microscopy techniques to see single molecules of telomerase in living cells.

A flaw in the replication of chromosomes means that they get shorter with each cell division. If nothing is done to correct this error, replication stops and cells go into a state called senescence, a hallmark of aging. Normally, telomerase adds extra DNA to the ends of chromosomes to prevent this problem, but as we age our bodies produce fewer of them.

Cancer cells, on the other hand, become immortal by switching telomerase back on, allowing cells to divide indefinitely. This re-activation is among the first steps that direct cells to become cancerous, but the process remains poorly understood. If researchers knew more about it, they could offer hope for some form of therapy to combat it.

Now an Université de Montréal team led by biochemistry professor Pascal Chartrand, in collaboration with cell biologist Agnel Sfeir at the Skirball Institute in New York, has succeeded in tagging telomerase with several ultrabright fluorescent molecules - something that's never been done before.

"With this technological breakthrough, we observed that telomerase continuously probes telomeres, but becomes engaged at the ends of chromosomes following a two-step binding mode," said UdeM biochemist Hadrien Laprade, who, with his colleague Emmanuelle Querido, conducted the experimental investigations.

In their study, the scientists also show how mutation of a telomeric regulatory factor results in an unrestrained access of telomerase to the tips of telomeres, an event that promotes tumorigenesis.

"This new technology now provides sufficient details of how a key actor in cancer works at the molecular level, the first step in developing novels therapeutic strategies to thwart its activity," said Chartrand.

"It could take years before we get there, but this is an important first step."

Facts, background information, dossiers
More about Université de Montréal
  • News

    Shaping the rings of molecules

    Macrocycles are molecules made of large rings of atoms. Despite being relatively big and flexible, the molecules don't always stay "floppy" -- they can actually lock themselves into specific shapes and geometries. In manufacturing, controlling the three-dimensional shapes of macrocycles is ... more

    Cancer treatment: A researcher makes breakthrough immunotherapy discovery

    Dr Christopher E. Rudd, a researcher at the Centre de recherche de l'Hôpital Maisonneuve-Rosemont (CR-HMR) and Université de Montréal, has discovered a new cell therapy approach that boosts the immune response of T lymphocytes to malignant tumours. "Our work has identified a new T-cell prot ... more

    Can gut infection trigger Parkinson's disease?

    A new study by Montreal scientists published in Nature demonstrates that a gut infection can lead to a pathology resembling Parkinson's disease (PD) in a mouse model lacking a gene linked to the human disease. This discovery extends recent work by the same group suggesting that PD has a maj ... more